In a small, open-label trial in people with mild to moderate, dominantly inherited Alzheimer’s disease (DIAD), the tau immunotherapy etalanetug almost abolished markers of neurofibrillary tangles in ...

THURSDAY, Dec. 11, 2025 (HealthDay News) -- Plasma phosphorylated tau 217 (p-tau217) can reliably detect Alzheimer disease (AD) pathology in the preclinical stage, according to a meta-analysis ...

Plasma phosphorylated tau 217 (p-tau217) can reliably detect Alzheimer disease (AD) pathology in the preclinical stage, according to a meta-analysis published online Dec. 1 in JAMA Neurology. Michael ...

TOKYO, Dec 2, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at ...

Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase Ib/II study TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai Co., ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...

Plasma phosphorylated tau 181 (p-tau181) could not only serve as a reliable biomarker for diagnosing Alzheimer's disease (AD) progression, but it could also identify those who were at risk of ...

New research by scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab), in collaboration with scientists from TAU Systems Inc., has brought the promise of ...

Elevated plasma p-tau217 signaled cognitive decline and dementia risk in people with Down syndrome. High p-tau217 and GFAP levels predicted future amyloid buildup. Down syndrome-related Alzheimer's ...

Researchers have discovered that newborns have high levels of the tau protein, which is elevated in older people with Alzheimer’s disease, but that it causes them no harm. The discovery opens the door ...